Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Theratechnologies Inc. (T:TH)

Business Focus: Biopharmaceuticals

Sector:  Healthcare Industry:  Pharmaceuticals
Company Contact
Address: 2015 Peel Street, 11th Floor
Tel: 1-438-3156608
IR: See website
Key People
Paul Levesque
President, Chief Executive Officer, Director
Philippe Dubuc
Chief Financial Officer, Senior Vice President
Christian Marsolais
Senior Vice President, Chief Medical Officer
Marienoel Colussi
Vice President - Finance
Andre Dupras
Vice President of Human Resources
Jocelyn Lafond
General Counsel, Company Secretary
John Leasure
Global Commercial Officer
Business Overview
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.
Financial Overview
For the six months ended 31 May 2024, Theratechnologies Inc revenues increased 2% to $38.3M. Net loss decreased 83% to $3.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Research and development expenses decrease of 57% to $8.5M (expense), G/L on debt restructuring decrease from $2.7M (expense) to $0K.
Employees: 103 as of Nov 30, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $121.60M as of May 31, 2024
Annual revenue (TTM): $112.97M as of May 31, 2024
EBITDA (TTM): $9.56M as of May 31, 2024
Net annual income (TTM): -$9.57M as of May 31, 2024
Free cash flow (TTM): -$5.19M as of May 31, 2024
Net Debt Last Fiscal Year: $31.87M as of May 31, 2024
Shares outstanding: 45,980,768 as of Jul 11, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization